Oritavancin

Medical uses

Oritavancin is considered a long-lasting antibiotic due to its extended half-life (up to ), high protein binding capacity, and ability to penetrate tissues effectively. It binds strongly to plasma proteins (around 85%), resulting in prolonged release into surrounding tissues. Furthermore, oritavancin exhibits excellent tissue penetration and distribution throughout various sites, including skin structures, synovial fluid (found in joints), bone tissue, and macrophages. Less frequent dosing requirements still keep efficacy against gram-positive infections, which is convenient for prolonged treatment courses such as osteoarticular infections and endocarditis, making it an option for outpatient antibiotic therapy in difficult-to-treat populations where adherence may be challenging and those with limited access to healthcare facilities.

''In vitro'' activity

Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. Oritavancin demonstrates in vitro activity against both the planktonic and biofilmstates of staphylococci associated with prosthetic joint infection (PJI), albeit with increased minimum biofilm bactericidal concentration (MBBC) compared to Minimum inhibitory concentrations (MIC) values. Moreover oritavancin has demonstrated activity against in vitro to vancomycin-susceptible enterococci (VSE) and vancomycin-resistant enterococci (VRE) in both planktonic and biofilm states.

Mechanism

The 4'-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria. It also acts by inhibition of transglycosylation and inhibition of transpeptidation.

Synergism

Several antibiotics have been tested as partner drugs of oritavancin. Among these "companions" drugs, fosfomycin displayed (in vitro and in vivo) synergistic activity when administered together with oritavancin against VRE strains (both vanA and vanB), including biofilm-producing isolates. This synergistic action has also been proposed for the prevention of vascular graft infections by impregnating prostheses with a combination of oritavancin and fosfomycin.

Spectrum of Activity

Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as Clostridioides difficile, Clostridium perfringens, Peptostreptococcus spp., and Cutibacterium acnes. Oritavancin's spectrum of activity shows similarities to vancomycin, but with lower minimum inhibitory concentrations (MIC).

History

Originally discovered and developed by Eli Lilly, oritavancin was acquired by Intermune in 2001, and then by Targanta Therapeutics in 2005.

In 2009, The Medicines Company acquired the development rights, completed clinical trials and submitted a new drug application to the FDA in February 2014. In August 2014, the US Food and Drug Administration approved oritavancin to treat skin infections.

A marketing authorization valid throughout the European Union was granted in March 2015, for the treatment of acute bacterial skin and skin structure infections in adults.

References

References

1. (12 September 2025). "Oritiniv Product information".
2. (12 September 2025). "Details for: Oritiniv".
3. (1 September 2012). "Summary Basis of Decision for Oritiniv".
4. "Orbactiv- oritavancin injection, powder, lyophilized, for solution".
5. "Kimyrsa- oritavancin diphosphate injection, powder, lyophilized, for solution".
6. (September 2009). "Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization". Biochimica et Biophysica Acta (BBA) - Biomembranes.
7. (6 August 2014). "FDA approves Orbactiv to treat skin infections". U.S. [[Food and Drug Administration]] (FDA).
8. (17 September 2018). "Orbactiv EPAR".
9. (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med.
10. (January 2007). "A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus". Journal of Drugs in Dermatology.
11. (June 2008). "Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens". Future Microbiology.
12. (March 2016). "Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections". Infectious Diseases and Therapy.
13. (September 2008). "Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax". Antimicrobial Agents and Chemotherapy.
14. (October 2018). "In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection". Diagnostic Microbiology and Infectious Disease.
15. (August 2018). "In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci". Diagnostic Microbiology and Infectious Disease.
16. (December 2010). "Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing". Antimicrobial Agents and Chemotherapy.
17. (April 2012). "Oritavancin: mechanism of action". Clinical Infectious Diseases.
18. (1 June 2015). "β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium". The Journal of Antimicrobial Chemotherapy.
19. (May 2019). "In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci". The Journal of Antimicrobial Chemotherapy.
20. (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant ''Enterococcus faecium''". Antibiotics.
21. (August 2023). "Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment". Journal of Chemotherapy.
22. (22 October 2024). "Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection". Pharmaceutics.
23. (March 2012). "Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010". Antimicrobial Agents and Chemotherapy.
24. (June 2014). "Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide". The Journal of Antimicrobial Chemotherapy.
25. (November 2009). "Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates". Antimicrobial Agents and Chemotherapy.
26. (9 May 2014). "The Daily Biopharmaceutical News Source". BioWorld.
27. (17 May 2011). "Biotechs pick up slack in antibiotics development".
28. (6 August 2014). "FDA approves Orbactiv to treat skin infections". U.S. [[Food and Drug Administration]] (FDA).
29. "EPAR summary: Orbactiv". European Medicines Agency.